Widespread testing for the coronavirus is still unfeasible, Roche’s CEO Severin Schwan said in a press briefing on the coronavirus outbreak from industry leaders.
Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with severe COVID-19 pneumonia, following independent research in China suggesting it may
The FDA thinks a dual-target antibody from Janssen could set new standards in treatment for certain patients with lung cancer, whose disease has progressed after chemotherapy and are unlike
Chinese authorities have issued guidelines recommending Roche’s anti-inflammation drug Actemra to combat severe complications caused by the COVID-19 coronavirus.
